ACTIVITY OF IAP ANTAGONIST DEBIO 1143 AS A MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE AGENTS IN MODELS OF HUMAN LUNG CANCER OF DIFFERENT HISTOTYPES

被引：0
|
作者：
Wiedemann, N. [1 ]
Langdon, C. G. [2 ]
Held, M. A. [2 ]
Platt, J. T. [2 ]
Zanna, C. [3 ,4 ]
Sorensen, M.
Wang, S. [5 ]
Bosenberg, M. W. [2 ]
Stern, D. F. [2 ]
Vuagniaux, G. [1 ]
机构：
[1] Debiopharm Int SA, Pharmacol & Screening, Lausanne, Switzerland
[2] Yale Univ, Sch Med, New Haven, CT USA
[3] Debiopharm Int SA, Med Affairs, Lausanne, Switzerland
[4] Ascenta Therapeut, R&D, Malvern, PA USA
[5] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2014年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
46P
引用
收藏
页码：S21 / S21
页数：1
相关论文
共 29 条
  • [1] Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer models
    Langdon, Casey G.
    Wiedemann, Norbert
    Held, Mathew A.
    Platt, James T.
    Levy, Frederic
    Robichon, Denis
    Zanna, Claudio
    Vuagniaux, Gregoire
    Sorensen, Mel
    Wang, Shaomeng
    Bosenberg, Marcus W.
    Stern, David F.
    CANCER RESEARCH, 2014, 74 (19)
  • [2] Effects of Debio 1143, a novel oral IAP inhibitor, in monotherapy and in combination with platinum drugs in human SCCHN tumor specimens
    Serova, Marie
    Tijeras-Raballand, Annemilai
    Albert, Sebastien
    Faivre, Sandrine
    Raymond, Eric
    Vaslin, Anne
    Zanna, Claudio
    Vuagniaux, Gregoire
    de Gramont, Armand
    CANCER RESEARCH, 2014, 74 (19)
  • [3] A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells.
    Langdon, Casey G.
    Wiedemann, Norbert
    Held, Mathew A.
    Platt, James T.
    Levy, Frederic
    Zanna, Claudio
    Vuagniaux, Gregoire
    Sorensen, Mel
    Wang, Shaomeng
    Bosenberg, Marcus W.
    Stern, David F.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [4] The WEE1 inhibitor Debio 0123 enhances the efficacy of standard of care DNA damaging agents in lung cancer models
    Piggott, Luke
    Vaslin-Chessex, Anne
    Luong, Noemie
    Tschumi, Benjamin
    Vuagniaux, Gregoire
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Anti-cancer activity of onconase, a cytotoxic amphibian ribonuclease, in combination with standard of care agents in non-small cell lung tumorgraft models
    Bruckheimer, E. M.
    Strawn, S. J.
    Wick, M. J.
    Nieves, F.
    Saxena, S.
    Ardelt, W.
    Rowinsky, E. K.
    Sidransky, D.
    EJC SUPPLEMENTS, 2010, 8 (07): : 137 - 137
  • [6] Preclinical activity of Vintafolide/MK-8109 monotherapy and in combination with standard of care therapy in triple-negative breast cancer models
    Haines, Brian B.
    O'Neil, Jennifer
    Hinton, Marlene C.
    Ware, Christopher
    Yeh, Tammie C.
    Sun, Tianxiao
    Picard, Kristen L.
    Zhang, Theresa
    Schmidt, Emmett V.
    Dussault, Isabelle
    CANCER RESEARCH, 2014, 74 (19)
  • [7] Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models
    Van Laar, ES
    Weitman, S
    MacDonald, JR
    Waters, SJ
    PROSTATE, 2004, 59 (01): : 22 - 32
  • [8] Onconase, a cytotoxic ribonuclease, in combination with standard of care agents in non-small cell lung tumorgraft models
    Loyo, M.
    Bruckheimer, E.
    Strawn, S. J.
    Wick, M. J.
    Nieves, F.
    Saxena, S. K.
    Hidalgo, M.
    Ardelt, W.
    Rowinsky, E. K.
    Sidransky, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy and in combination with multiple standard of care agents in various solid cancer models
    Tameire, Feven
    Wojnarowicz, Paulina
    Dudgeon, Crissy
    Fujisawa, Sho
    Huang, Sharon
    Reilly, Owen B.
    Collette, Nicholas
    Drees, Jeremy
    Bieging-Rolett, Kathryn
    Kangas, Takashi O.
    Zhang, Weiyu
    Fumagalli, Maria
    Dewji, Iman
    Li, Yunfang
    Chan, Anissa S. H.
    Qiu, Xiaohong
    Harrison, Ben
    LaCayo, Ashley
    Cordova, Ricardo A.
    Staschke, Kirk A.
    Rigby, Alan C.
    Ramurthy, Savithri
    Lightcap, Eric S.
    Surguladze, David
    Bose, Nandita
    CANCER RESEARCH, 2023, 83 (07)
  • [10] AMG 176 exhibits robust antitumor activity in combination with standard of care agents in models of acute myeloid leukemia
    Caenepeel, Sean
    Belmontes, Brian
    Osgood, Tao
    Cajulis, Elaina
    Coxon, Angela
    Canon, Jude
    Hughes, Paul E.
    CANCER RESEARCH, 2019, 79 (13)
123